General Endocrinology

SAT-846 - A Longitudinal Study of New-Onset Diabetes Mellitus Following COVID-19 Infection Compared with Non-COVID-19 Infected Patients at A NYC Hospital, January 2021-June 2023

Saturday, June 13, 2026

9:30 AM - 4:30 PM CT

Location: ENDOExpo; Poster Floor

Abstract Poster Presenter(s)

Danelly Gomez D' Aza, MD

Endrocrinology, Diabetes and Metabolism fellow
Lincoln Hospital
Bronx, NY, United States

Co-Author(s)

Danelly Gomez D' Aza, MD

Endrocrinology, Diabetes and Metabolism fellow
Lincoln Hospital
Bronx, NY, United States
TM

Tawana Mazhude, MD

Endocrinology Fellow
MONTEFIORE MEDICAL CENTER
New York, New York, United States
FA

Faridat Abdulkarim, MD

Lincoln Medical and Mental Health Center/NYCHHC
Bronx, United States
LR

Liya Rafeekh, MD

Internal Medicine Resident
Lincoln Medical and Mental Health Center/NYCHHC
Nyc, New York, United States
FA

Fnu Aiysha, MBBS

Resident
Lincoln Medical and Mental Health Center/NYCHHC
bronx, New York, United States
FA

Faiq Aldarabah, MD

Lincoln Medical and Mental Health Center/NYCHHC
Yonkers, New York, United States
HY

Hala Yousef, MD

Lincoln Medical and Mental Health Center/NYCHHC
bronx, United States
LK

Lavina Khemani, MD

Lincoln Medical and Mental Health Center/NYCHHC
bronx, United States
DA

Dania Abu Zahra, MD

Lincoln Medical and Mental Health Center/NYCHHC
bronx, United States
HO

Han Oo, MPH

Lincoln Medical and Mental Health Center/NYCHHC
bronx, United States
ZT

Zahra Tasneem, MD

Lincoln Hospital
bronx, United States
JV

Julia Vargas-Jerez, MD

Lincoln Hospital
bronx, United States

Senior Author/Primary Investigator(s)

Vm

Vidya menon, MD

Attending Physician
Lincoln Medical and Mental Health Center/NYCHHC
bronx, United States

Co-Author(s)

Vm

Vidya menon, MD

Attending Physician
Lincoln Medical and Mental Health Center/NYCHHC
bronx, United States

Disclosure(s):

Danelly Gomez D' Aza, MD: No financial relationships to disclose

Background
Emerging evidence suggests an association between COVID infection and dysglycemia; however, data comparing the longitudinal course of new-onset diabetes following COVID infection versus new-onset diabetes unrelated to COVID remain limited. We aimed to compare clinical characteristics, glycemic trajectories, and treatment patterns among patients with new-onset diabetes with and without prior COVID infection.

Methods
We conducted a single-center retrospective observational study including adults diagnosed with new-onset diabetes mellitus (type 1 or type 2) between Jan-2021 and Jun-2023. Patients were grouped into two cohorts based on history of COVID infection prior to diabetes diagnosis versus no history of COVID. Electronic medical records were reviewed for demographic and clinical characteristics, HbA1c trends and diabetes medications. We compared mixed effects models with and without a COVID-by-time interaction using likelihood ratio tests to determine whether medication trajectories differed by COVID status. Analysis was conducted in R Studio.

Results
A total of 458 patients with new-onset diabetes were included. Baseline characteristics were similar except ethnicity, with more Hispanics in COVID vs non-COVID (85% vs 69%, p = 0.009). Median HbA1c in non-COVID vs COVID was 7.1 vs 7.0 at diagnosis, 6.55 vs 6.2 at 3 months, and 6.5 vs 6.8 at 6 months, all not statistically significant. At diagnosis, DKA (9.8% vs 4.5%) and HHS (3.3% vs 0.5%) were more frequent in COVID; (overall p=0.052). Insulin use at diagnosis was higher in COVID patients (21% vs 14%) but declined similarly over time in both groups. In adjusted mixed-effects models, GLP-1RA use increased at 6 months follow up compared to baseline (OR 6.4, p=0.017), driven by higher baseline A1c (OR 1.73, p=0.005) and female sex (male OR 0.07, p=0.042), with no COVID or COVID×time effect. COVID was associated with lower baseline DPP-4i use (β −5.23, p=0.008), while baseline A1c predicted their use (β 1.01, p< 0.001), with no time or interaction effects. SGLT2i use was rare at baseline (OR≈10⁻⁶) but increased after 3 months (OR 16.1) and 6 months (OR 63.5), independent of COVID status; baseline A1c predicted it’s use (OR 1.42, p=0.006). Sulfonylurea use was rare (OR≈5×10⁻⁵) with no COVID or time effects but increased with higher A1c (OR 1.46, p=0.002). COVID was associated with lower baseline metformin use (adjusted OR 0.06, p< 0.001), while higher A1c increased its use while age decreased its use, time and COVID×time effects were not significant after adjustment.

Conclusion
In this single-center cohort, COVID-associated new-onset diabetes was associated with higher rates of hyperglycemic emergencies at diagnosis, but similar glycemic trajectories and treatment patterns compared with non-COVID diabetes. Medication use was driven by HbA1c and demographics than to COVID status, supporting standard diabetes management.

*Unless otherwise noted, all abstracts presented at ENDO must not be released to the press or the public until the date and time of presentation. For oral presentations, the abstracts are embargoed until the session begins. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO.*